Showing results (471-480 of 484) with videos related to
Sort By:
Pageof 49
Cancer Discovery|April 29, 2025
Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung CancerEverett J Moding, Mohammad Shahrokh Esfahani, Cheng Jin, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort studyM M Zheng, Y Xia, K Pan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2020
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D Hellmann, Barzin Y Nabet, Hira Rizvi, et al.Immunity|March 10, 2021
Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discoveryShin-Heng Chiou, Diane Tseng, Alexandre Reuben, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort ABenjamin Besse, Koichi Goto, Yongsheng Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET RegistryOliver Gautschi, Julie Milia, Thomas Filleron, et al.Nature|April 16, 2025
An ultrasensitive method for detection of cell-free RNAMonica C Nesselbush, Bogdan A Luca, Young-Jun Jeon, et al.The Lancet. Digital Health|June 2, 2023
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B Saad, Lingzhi Hong, Muhammad Aminu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.Pageof 49